PreciThera raises C$36M in series A

Orphan bone disease newco PreciThera Inc. (Montreal, Canada) raised C$36 million ($28.6 million) in an oversubscribed series A round led by Arix Bioscience. Sanderling Ventures, Fonds de solidarité FTQ, CTI Life Sciences Fund and Emerillion Capital also participated.

The company is developing targeted biologics for orphan bone diseases. CEO Pierre Beauparlant told BioCentury that current treatments are non-specific, targeting symptoms rather than root genetic causes. PreciThera's informatics-based strategy combines in silico RNA sequencing with genomic and clinical data to validate pathways responsible for bone dysfunction disorders...